Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury

Inclusion Criteria: * patients have a definite diagnosis of live cirrhosis and AKI; * patients present with AGIB at admission; * patients' age 18-70 years old; * patients or relatives can sign the informed consent form. Exclusion Criteria: * patients have hepatorenal syndrome- acute renal injury (HRS-AKI); * patients have structural kidney injury; * patients have chronic kidney disease; * patients received terlipressin or somatostatin therapy within 48 hours before enrollment; * patients received kidney replacement therapy before enrollment; * patients have a history of liver transplantation or TIPS; * patients have acute liver failure or acute-on-chronic liver failure; * patients have hepatic or renal malignant tumor; * patients have severe diseases of the heart, lungs, and brain; * patients have contraindications for experimental drugs; * patients are in pregnancy or lactation; * patients participated in other clinical studies within 3 months before enrollment; * patients have other conditions that investigators deem unsuitable for enrollment in the study.